Dopaminergic treatment strategies for people with Parkinson's disease in Europe: a retrospective analysis of PRISM trial data.
Lara HansenVictoria WitzigJörg B SchulzFlorian HoltberndPublished in: Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology (2023)
The relative lack of socio-economic variables affecting prescription practice in the study sample and limited model accuracy to predict treatment class suggest the presence of additional, country-specific factors affecting prescription patterns that were not assessed in the PRISM trial. Our findings indicate that physicians still avoid prescribing LD monotherapy to younger PD patients.
Keyphrases
- primary care
- end stage renal disease
- study protocol
- phase iii
- clinical trial
- ejection fraction
- newly diagnosed
- phase ii
- chronic kidney disease
- healthcare
- prognostic factors
- peritoneal dialysis
- open label
- emergency department
- electronic health record
- machine learning
- combination therapy
- randomized controlled trial
- patient reported outcomes
- replacement therapy